MedTrace Logo

One Year Trial Evaluating Safety of Ozurdex With Eylea

NCT03984110 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-10

No results posted yet for this study

Summary

One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)

Conditions

Interventions

DRUG

Ozurdex

Intravitreal injection

DRUG

Eylea

Intravitreal injection

Sponsors & Collaborators

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • Texas Retina Associates

    lead OTHER

Principal Investigators

  • Ashkan M Abbey, MD · Texas Retina Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2022-10-27
Completion
2022-10-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984110 on ClinicalTrials.gov